Chapter 11 Restructuring

23andMe’s Chapter 11 bankruptcy filing signals a high-stakes effort to stabilize operations, maximize business value through a court-supervised sale, and safeguard customer data. This article explores the financial, legal, and governance challenges confronting the genomics pioneer as it seeks to reposition amidst turbulent market conditions.